Table 1.
Demographic and Clinical Characteristics of Children with IBD
| Ulcerative Colitis n=43 (63.2%) |
Crohn’s Disease n=25 (36.8%) |
||
|---|---|---|---|
| Gender | Boys | 20 (46.5%) | 13 (52%) |
| Girls | 23 (53.5%) | 12 (48%) | |
| Age (years) | Mean: 13.6±3.4 | Mean: 13.7±2.6 | |
| Median: 14.5 | Median: 13.5 | ||
| Range: 6.5–18 | Range: 8.5–18 | ||
| Clinical activity of IBD | Active | 23 (53.5%) | 16 (64%) |
| Remission | 20 (46.5%) | 9 (36%) | |
| IBD disease activity indexes | PCDAI | – | Mean: 28±21.9 pts |
| Median: 30 pts | |||
| Range: 0–65 pts | |||
| PUCAI | Mean: 24.6±22.9 pts | – | |
| Median: 20 pts | |||
| Range: 0–75 pts | |||
| IBD location according to Paris classification | L1 | – | 2 (8%) |
| L2 | 5 (20%) | ||
| L3 | 7 (28%) | ||
| L3+L4a | 11 (44%) | ||
| E1 | 2 (4.6%) | – | |
| E2 | 4 (9.3%) | ||
| E3 | 7 (16.3%) | ||
| E4 | 30 (69.8%) | ||
| Treatment | EEN | N/A | 4 (16%) |
| 5ASA | 13 (30.2%) | 2 (8%) | |
| AZA | 0 (0%) | 2 (8%) | |
| 5ASA+AZA | 7 (16.4%) | 2 (8%) | |
| 5ASA+GCS | 5 (11.6%) | 0 (0%) | |
| 5ASA+ GCS+AZA | 5 (11.6%) | 1 (4%) | |
| IFX | 0 | 2 (8%) | |
| Treatment naïve | 13 (30.2%) | 12 (48%) | |
Abbreviations: EEN, exclusive enteral nutrition; 5ASA, 5-aminosalicylate; AZA, azathioprine; GCS, glucocorticoids; IFX, infliximab.